425 related articles for article (PubMed ID: 8351515)
41. Inhibition of phage phi 29 assembly by antisense oligonucleotides targeting viral pRNA essential for DNA packaging.
Zhang C; Garver K; Guo P
Virology; 1995 Aug; 211(2):568-76. PubMed ID: 7645260
[TBL] [Abstract][Full Text] [Related]
42. Specific inhibition of nitric oxide production in macrophages by phosphorothioate antisense oligonucleotides.
Arima H; Sakamoto T; Aramaki Y; Ishidate K; Tsuchiya S
J Pharm Sci; 1997 Oct; 86(10):1079-84. PubMed ID: 9344161
[TBL] [Abstract][Full Text] [Related]
43. Antisense phosphorothioate oligodeoxynucleotides targeted to the vpr gene inhibit human immunodeficiency virus type 1 replication in primary human macrophages.
Balotta C; Lusso P; Crowley R; Gallo RC; Franchini G
J Virol; 1993 Jul; 67(7):4409-14. PubMed ID: 8510229
[TBL] [Abstract][Full Text] [Related]
44. Antisense oligonucleotides in cutaneous therapy.
Wraight CJ; White PJ
Pharmacol Ther; 2001 Apr; 90(1):89-104. PubMed ID: 11448727
[TBL] [Abstract][Full Text] [Related]
45. Synthetic oligonucleotides: the development of antisense therapeutics.
Monteith DK; Levin AA
Toxicol Pathol; 1999; 27(1):8-13. PubMed ID: 10367666
[TBL] [Abstract][Full Text] [Related]
46. Antisense oligodeoxynucleotide complementary to CXCR4 mRNA block replication of HIV-1 in COS cells.
Kusunoki A; Wada A; Kurosaki N; Kimura T; Takai K; Yamamoto N; Takaku H
Nucleosides Nucleotides; 1999; 18(6-7):1705-8. PubMed ID: 10474251
[TBL] [Abstract][Full Text] [Related]
47. Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization.
Yaida Y; Nowak TS
Regul Pept; 1995 Oct; 59(2):193-9. PubMed ID: 8584754
[TBL] [Abstract][Full Text] [Related]
48. Translation inhibition by phosphorothioate oligodeoxynucleotides in cell-free systems.
Ghosh MK; Ghosh K; Cohen JS
Antisense Res Dev; 1992; 2(2):111-8. PubMed ID: 1327332
[TBL] [Abstract][Full Text] [Related]
49. G3139, a BCL-2 antisense oligo-nucleotide, in AML.
Marcucci G; Stock W; Dai G; Klisovic MI; Maharry K; Shen T; Liu S; Sher DA; Lucas D; Zwiebel A; Larson RA; Caligiuri MA; Bloomfield CD; Chan KK; Grever MR; Byrd JC
Ann Hematol; 2004; 83 Suppl 1():S93-4. PubMed ID: 15124691
[No Abstract] [Full Text] [Related]
50. Specific inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by liposomally endocapsulated antisense phosphorothioate oligonucleotides: penetration and localization of oligonucleotides in clone 76 cells.
Hatta T; Takai K; Nakada S; Yokota T; Takaku H
Biochem Biophys Res Commun; 1997 Mar; 232(2):545-9. PubMed ID: 9125219
[TBL] [Abstract][Full Text] [Related]
51. Modulation of plasminogen activator inhibitor type-1 biosynthesis in vitro and in vivo with oligo(nucleoside phosphorothioate)s and related constructs.
Buczko W; Cierniewski C; Kobylańska A; Koziołkiewicz M; Okruszek A; Pawłowska Z; Pluskota E; Stec WJ
Pharmacol Ther; 1997; 76(1-3):161-75. PubMed ID: 9535178
[TBL] [Abstract][Full Text] [Related]
52. Liposomal delivery of oligodeoxynucleotides.
Tari A; Khodadadian M; Ellerson D; Deisseroth A; Lopez-Berestein G
Leuk Lymphoma; 1996 Mar; 21(1-2):93-7. PubMed ID: 8907275
[TBL] [Abstract][Full Text] [Related]
53. A new class of anti-HIV-1 oligonucleotide targeted to the polypurine tract of viral RNA.
Hiratou T; Miyano-Kurosaki N; Gushima H; Takaku H
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):715-8. PubMed ID: 11563099
[TBL] [Abstract][Full Text] [Related]
54. The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1.
Yamaguchi K; Papp B; Zhang D; Ali AN; Agrawal S; Byrn RA
AIDS Res Hum Retroviruses; 1997 May; 13(7):545-54. PubMed ID: 9135872
[TBL] [Abstract][Full Text] [Related]
55. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems.
Summerton J; Stein D; Huang SB; Matthews P; Weller D; Partridge M
Antisense Nucleic Acid Drug Dev; 1997 Apr; 7(2):63-70. PubMed ID: 9149841
[TBL] [Abstract][Full Text] [Related]
56. Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity.
Tang JY; Temsamani J; Agrawal S
Nucleic Acids Res; 1993 Jun; 21(11):2729-35. PubMed ID: 8392706
[TBL] [Abstract][Full Text] [Related]
57. Pseudo-cyclic oligonucleotides: in vitro and in vivo properties.
Jiang Z; Kandimalla ER; Zhao Q; Shen LX; DeLuca A; Normano N; Ruskowski M; Agrawal S
Bioorg Med Chem; 1999 Dec; 7(12):2727-35. PubMed ID: 10658577
[TBL] [Abstract][Full Text] [Related]
58. Vmw65 phosphorothioate oligonucleotides inhibit HSV KOS replication and Vmw65 protein synthesis.
Kmetz ME; Ceruzzi M; Schwartz J
Antiviral Res; 1991 Sep; 16(2):173-84. PubMed ID: 1665960
[TBL] [Abstract][Full Text] [Related]
59. Bispecific oligonucleotides may induce interferon expression in LNCaP cells enhancing surface antigen expression: effect of intrastrand base pair complementarity.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2011; 25(1):61-7. PubMed ID: 21282736
[TBL] [Abstract][Full Text] [Related]
60. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
Henry SP; Miner RC; Drew WL; Fitchett J; York-Defalco C; Rapp LM; Levin AA
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2646-51. PubMed ID: 11581212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
